Advances in the application of direct-acting antivirals in patients with hepatitis C cirrhosis
- VernacularTitle:直接抗病毒药物在丙型肝炎肝硬化患者中的应用进展
- Author:
Xiping RAN
1
;
Dachuan CAI
Author Information
- Keywords: Hepacivirus; Liver Cirrhosis; Direct-Acting Antivirals; Treatment Outcome
- From: Journal of Clinical Hepatology 2024;40(8):1682-1687
- CountryChina
- Language:Chinese
- Abstract: Chronic hepatitis C virus(HCV)infection can lead to liver cirrhosis,and complications after liver cirrhosis,including hepatocellular carcinoma(HCC),are the leading causes of death in patients with chronic liver diseases.Antiviral therapy can help to realize sustained virologic response,improve hepatitis and liver fibrosis,and delay disease progression.The safety and efficacy of direct-acting antivirals(DAAs)have been confirmed in patients with HCV-related liver cirrhosis,and whether DAAs can improve the complications and prognosis of patients with liver cirrhosis has gradually become a research hotspot.Related data are mainly reported by foreign scholars,and since DAAs have not been marketed in China for a long time,there is still a lack of mid-and long-term data.This article reviews the latest studies on the application of DAAs in patients with HCV-related liver cirrhosis and the impact of DAAs on clinical prognosis.
